RxDoctor Payments Data

Laurel Zulliger, MD

Family Medicine · Columbus, OHNPI 1508963059

Payments from drug & device makers

$261in general payments, 2019–2025

Across 12 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$109
  • AstraZeneca$50
  • Novo Nordisk$30
  • Pfizer$21
  • Abbott$14
  • GSK$14
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$261 in reported general payments places this provider in the 40th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$71,398
Medicare patients
185
Services billed
1,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$111,105
EliquisApixaban94$82,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$35,248
JardianceEmpagliflozin36$30,344
Synjardy XrEmpagliflozin/Metformin Hcl34$27,465
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$14,700
MyrbetriqMirabegron14$7,845
MotegrityPrucalopride Succinate12$6,409
FetzimaLevomilnacipran Hcl11$5,071
Rosuvastatin Calcium300$4,941
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,548
Humalog Kwikpen U-100Insulin Lispro11$3,439
Losartan Potassium246$2,725
Albuterol Sulfate HfaAlbuterol Sulfate96$2,662
Atorvastatin Calcium245$2,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$30$111,10586 claims
PfizerEliquis$21$82,29894 claims
GSKTrelegy Ellipta$14$35,24836 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$11$6,40912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →